Fractyl Health (GUTS) Chardan's 8th Annual Genetic Medicines Conference summary

Strategic focus and differentiation

• Targeting obesity and type 2 diabetes by aiming to eradicate disease, not just manage it, through therapies addressing root causes.

• Revita, a duodenal mucosa ablation device, is approved in Europe, reimbursed in Germany, and in late-stage US development with pivotal data expected in 2025.

• Rejuva, a one-time pancreatic gene therapy, is set for first-in-human studies in 2025, with preclinical data showing superior durability and potency over GLP-1 drugs.

• Both assets are designed to offer sustained solutions, addressing the unmet need for weight maintenance rather than just weight loss.

• Management has deep experience in biotech, gene therapy, and medical devices, with $102 million in cash as of June, providing runway into Q4 2025.

Market landscape and unmet needs

• GLP-1 drugs dominate the market but suffer from high discontinuation rates and rapid weight regain, with less than half of users remaining on therapy at 12 weeks.

• Chronic drug therapy only addresses about half of the obesity population, leaving 50 million in the US unable or unwilling to take lifelong medication.

• Insurers are concerned about poor real-world adherence and outcomes, challenging the value proposition of reimbursing GLP-1 therapies.

• The largest unmet need has shifted from weight loss to durable weight maintenance, which current drugs do not address.

Clinical and preclinical progress

• Revita registry data in Europe shows 13% total body weight loss and significant A1c reduction at one year, with good tolerability.

• US pivotal study (Remain-1) is enrolling, with a planned midpoint analysis in Q2 2025; design includes GLP-1-naïve obese patients achieving weight loss, then randomized to Revita or sham.

• Revitalize-1 study is underway for type 2 diabetes, focusing on A1c reduction in patients avoiding further medication or insulin.

• Preclinical Rejuva data in mice and large animals show durable weight maintenance and blood sugar control after a single dose, outperforming chronic semaglutide.

• Proprietary endoscopic delivery enables low-dose, targeted gene therapy, reducing cost and improving safety profile.